Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ)
Huzhou, CN
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.99% | -2.61% | -9.07% | -17.28% | -19.03% | -14.42% | -13.78% | +5.25% | +78.45% | +68.45% | +230.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+18.0% ★ Q1'26: +8.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+24.7% Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.0% ★ Q1'26: +2.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+26.2% ★ Q1'26: +28.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+20.9% ★ Q1'26: +24.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.79× ★ Q1'26: 0.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
670.86M
est: 686.00M (-2.2%)
|
840.04M
est: 772.00M (+8.8%)
|
679.04M
est: 686.00M (-1.0%)
|
730.26M
est: 772.00M (-5.4%)
|
911.16M
est: 902.00M (+1.0%)
|
1.09B
est: 1.08B (+1.2%)
|
1.81B
est: 1.85B (-2.6%)
|
1.94B
est: 1.96B (-0.7%)
|
2.58B
est: 2.58B (0.0%)
|
3.04B
est: 3.23B (-6.0%)
|
3.93B
3.87B – 3.99B
+21.4% YoY
|
4.71B
4.64B – 4.79B
+20.0% YoY
|
| EBITDA |
116.73M
est: 145.60M (-19.8%)
|
101.52M
est: 163.86M (-38.0%)
|
101.69M
est: 145.60M (-30.2%)
|
79.84M
est: 163.86M (-51.3%)
|
95.91M
est: 191.45M (-49.9%)
|
171.31M
est: 228.80M (-25.1%)
|
378.43M
est: 393.30M (-3.8%)
|
483.23M
est: 415.23M (+16.4%)
|
657.69M
est: 614.43M (+7.0%)
|
873.44M
est: 770.57M (+13.4%)
|
935.82M
921.22M – 950.42M
+21.4% YoY
|
1.12B
1.11B – 1.14B
+20.0% YoY
|
| EBIT |
86.50M
est: 121.55M (-28.8%)
|
64.84M
est: 136.78M (-52.6%)
|
62.62M
est: 121.55M (-48.5%)
|
37.35M
est: 136.78M (-72.7%)
|
47.57M
est: 159.82M (-70.2%)
|
117.46M
est: 191.00M (-38.5%)
|
321.71M
est: 328.32M (-2.0%)
|
421.66M
est: 346.63M (+21.6%)
|
590.51M
est: 536.50M (+10.1%)
|
796.99M
est: 672.84M (+18.5%)
|
817.13M
804.38M – 829.88M
+21.4% YoY
|
980.94M
965.63M – 996.24M
+20.0% YoY
|
| Net Income |
84.77M
est: 97.38M (-12.9%)
|
72.02M
est: 118.25M (-39.1%)
|
45.14M
est: 97.38M (-53.6%)
|
20.75M
est: 118.25M (-82.5%)
|
25.59M
est: 146.07M (-82.5%)
|
88.80M
est: 180.85M (-50.9%)
|
273.01M
est: 278.23M (-1.9%)
|
382.94M
est: 380.25M (+0.7%)
|
507.77M
est: 517.35M (-1.9%)
|
631.93M
est: 652.77M (-3.2%)
|
828.11M
804.45M – 851.77M
+26.9% YoY
|
961.79M
942.28M – 981.30M
+16.1% YoY
|
| SGA |
358.86M
est: 332.67M (+7.9%)
|
418.73M
est: 374.38M (+11.8%)
|
377.96M
est: 332.67M (+13.6%)
|
411.34M
est: 374.38M (+9.9%)
|
527.65M
est: 437.42M (+20.6%)
|
601.17M
est: 522.77M (+15.0%)
|
921.45M
est: 898.60M (+2.5%)
|
874.18M
est: 948.72M (-7.9%)
|
949.08M
est: 1.15B (-17.6%)
|
1.09B
est: 1.44B (-24.5%)
|
1.75B
1.73B – 1.78B
+21.4% YoY
|
2.10B
2.07B – 2.14B
+20.0% YoY
|
| EPS |
0.15
est: 0.14 (+7.1%)
|
0.12
est: 0.17 (-29.4%)
|
0.07
est: 0.14 (-50.4%)
|
0.03
est: 0.17 (-79.9%)
|
0.04
est: 0.21 (-80.0%)
|
0.15
est: 0.26 (-43.9%)
|
0.39
est: 0.40 (-2.5%)
|
0.55
est: 0.55 (+0.6%)
|
0.73
est: 0.75 (-2.0%)
|
0.92
est: 0.94 (-2.1%)
|
1.19
1.16 – 1.23
+26.9% YoY
|
1.39
1.36 – 1.41
+16.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 129.1K | 0.65% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 238.5K | 0.39% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 349.8K | 0.06% |
| 4 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.00% | 10.5K | 0.44% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.1K | 0.44% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 111.9K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.2K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 25.3K | 0.26% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 74.5K | 0.29% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.25M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guofu Feng | Executive Vice President, Board Secretary & Non-Independent Director | — | male |
| Jian Chen | Deputy General Manager | — | female |
| Tao Wang | GM & Non-Independent Director | — | male |
| Xiao Guo Peng | Deputy General Manager | — | male |
| Xin Tan | Deputy General Manager | — | female |
| Yuehong Shen | Deputy GM & Non-Independent Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300181.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
